India’s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralizes both Alpha and Delta variants of Corona virus, the U.S.’ National Institute of Health has said.
The National Institute of Health said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 & B.1.617 variants of SARS-CoV-2.
The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
The collaboration between Dr David and Bharat Biotech International Ltd. of Hyderabad was initiated during a 2019 meeting in India coordinated by the National Institute of Allergy and Infectious Diseases (NIAID) Office of Global Research under the auspices of NIAID’s Indo-US Vaccine Action Program.